Domain Therapeutics and Ono Sign Collaboration Agreement
News Oct 23, 2012
Domain Therapeutics S.A. has announced that Domain Therapeutics and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) have signed a collaboration agreement focused on discovering small molecules targeting G-Protein Coupled Receptors (GPCRs).
Under the agreement, Ono will provide Domain Therapeutics with an upfront payment, pay research funding for the collaborative research programs and success-based milestones on the research and development progress, as well as royalties on sales of the products.
Domain Therapeutics will apply DTect-All™, its proprietary GPCR drug discovery platform, and its expertise in GPCR medicinal chemistry and pharmacology to design and optimize small molecules into drug candidates having activity against GPCRs selected by Ono.
Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration.
“This collaboration with Ono further confirms the value of our differentiated drug discovery process and of our expertise in the field of GPCRs. It constitutes an important step towards the objective of Domain Therapeutics to collaborate with pharma partners on integrated projects, from target to drug candidate,” said Pascal Neuville, CEO of Domain Therapeutics.
Neuville continued, “We are delighted to be collaborating with Ono, which is recognized as a leading Japanese pharmaceutical company.”
Kazuhito Kawabata, Ph.D., member of the board of directors, executive officer and executive director, discovery and research of Ono said: “We highly appreciate Domain Therapeutics’ DTect-All™ technology and strongly believe that the company is the partner of choice to identify GPCR drugs. This collaboration will strengthen Ono’s drug discovery capability in research areas of Ono’s expertise with significant unmet medical needs. We are expecting that innovative drugs will be created through this collaboration.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018